Caner ARSLAN, Öner SÜZER, Ahmet Kürşat BOZKURT, Özgür Özerk AKGÜN

The effects of calcium dobesilate and micronized purified flavonoid fractions on myocardial protection

Amaç: Kalsiyum dobesilat (DOBE) ve mikronize pürifiye flavanoid fraksiyonlarının (MPFF) iskemi ve reperfüzyon sonrası sıçan kalplerinin fonksiyonları üzerindeki etkileri araştırıldı. Çalışma planı: On sekiz adet Wistar albino cinsi erkek sıçan randomize olarak üç gruba ayrıldı: DOBE (100 mg/kg/gün), MPFF (100 mg/kg/gün) ve kontrol grubu. On beş dakikalık iskemiden önce ve sonra kalpler iki kez 25 dakika perfüze edildi. Koroner perfüzatlarda kreatin kinaz, laktat dehidrogenaz, troponin I ve miyoglobin seviyeleri, miyokard doku örneklerinde ise malondialdehid ve glutatyon düzeyleri analiz edildi. Ortalama P (koroner arterleri perfüze eden ortalama basınç), PP (pik sistolik basınç), (+)dp/dtmax (kontraksiyon kuvvetinin zamanla değişimi), (–)dp/dtmax (relaksasyon kuvvetinin zamanla değişimi), PP’ye ulaşılana kadar geçen süre, ejeksiyon zamanı ve kontraksiyon zamanı hesaplandı. Bulgular: DOBE grubunda reperfüzyonun 1. ve 5. dakikalarındaki ortalama ‘p’ değerleri kontrol grubundakilerden anlamlı derecede düşük idi; ayrıca 15., 20. ve 25. dakikalarda PP, (+)dp/dtmax ve (–)dp/dtmax ölçümleri ise kontrol grubundakilerden anlamlı derecede yüksek bulundu. MPFF grubunda ise (–)dp/dtmax değeri reperfüzyonun 5. dakikasında kontrol grubundakilere göre anlamlı ölçüde daha yüksek idi. Sonuç: DOBE iskemi ve reperfüzyon sonrası miyokard fonksiyonlarını iyileştirmede yararlıdır.

Kalsiyum dobesilat ve mikronize pürifiye flavonoid fraksiyonlarının miyokardın korunması üzerine etkileri

Background: We aimed to investigate the effects of calcium dobesilate (DOBE) and micronized purified flavonoid fractions (MPFF) on the functions of rat hearts following ischemia and reperfusion. Methods: Eighteen male Wistar albino rats were randomly divided into three groups: the DOBE group (100 mg/kg/ day), the MPFF group (100 mg/kg/day), and the control group . The hearts were perfused twice for 25 minutes before and after 15 minutes of ischemia. Creatine kinase, lactate dehydrogenase, troponin I and myoglobin levels in the coronary perfusates, and malondialdehyde and glutathione levels in the myocardial tissue samples were analyzed. Mean P (mean pressure perfusing coronary arteries), PP (peak systolic pressure), (+)dp/dtmax (contraction strength change over time), (–)dp/dtmax (relaxation strength change over time), time to reach PP, ejection time, and contraction time were calculated. Results: The mean ‘p’ values of the DOBE group were significantly lower than those of the control group at the first and fifth minutes of reperfusion; moreover, PP, (+)dp/ dtmax, and (–)dp/dtmax values were found to be significantly higher than the measurements made at the 15th, 20th and 25th minutes in the control group. In the MPFF group, the (–)dp/dtmax value was significantly higher than that of the control group at the fifth minute of reperfusion. Conclusion: DOBE is helpful in improving myocardial functions following ischemia and reperfusion.

PDF

___

1. Bolli R, Hartley CJ, Rabinovitz RS. Clinical relevance of myocardial “stunning”. Cardiovasc Drugs Ther 1991;5:877-90.
2. Mentzer RM, Jahania SM, Lasley RD. Myocardial protection. In: Edmunds HL Jr, Chon LH, editors. Cardiac surgery in the adult. 2nd ed. Philadelphia: McGraw-Hill; 2003. p. 413-38.
3. William A. Lell. Myocardial protection during cardiopulmonary bypass. In: Kaplan, editor. Cardiac anesthesia. 3rd ed. Philadelphia: W.B. Saunders Company; 1992. p. 1030-57.
4. Mauney MC, Cope JT, Binns OA, King RC, Shockey KS, Buchanan SA, et al. Non-heart-beating donors: a model of thoracic allograft injury. Ann Thorac Surg 1996;62:54-61.
5. Fleisher KJ, Baumgartner AW. Heart transplantation. In: Edmunds LH, editor. Cardiac Surgery in the adult. 1st ed. Philadelphia: McGraw-Hill; 1997. p. 1409-49.
6. Reddy VS, Drinkwater DC. Donor thoracic organs: evaluation, management and preservation. In: Franco KL, Vemer ED, editors. Advanced therapy in cardiac surgery. 2nd ed. New York: B.C. Decker Inc; 1999. p. 462-71.
7. Jurmann MJ, Schaefers HJ, Dammenhayn L, Haverich A. Oxygen-derived free radical scavengers for amelioration of reperfusion damage in heart transplantation. J Thorac Cardiovasc Surg 1988;95:368-77.
8. Cotran RS, Kumar V, Robbins SL. Cellular injury and cellular death. In: Schoen FJ, editor. Pathologic basis of disease. 5th ed. London: W.B. Saunders; 1994. p. 1-34.
9. Kehrer JP, Smith CV. Free radicals in biology: Sources, reactivities and roles in the etiology of human diseases. In: Frei B, editor. Natural antioxidants in human health and disease. 1st ed. San Diego: Academic Press; 1994. p. 25-62.
10. De Courten A. Doxium® in capillary dysfunctions. OM Medical Digest 1979;1:1-5.
11. Labrid CL, Perdrix L. Mechanism of oedema: activity of Daflon 500 mg. Phlebology 1992;2:30-9.
12. Angel MF, Ramasastry SS, Swartz WM, Narayanan K, Kuhns DB, Basford RE, et al. The critical relationship between free radicals and degrees of ischemia: evidence for tissue intolerance of marginal perfusion. Plast Reconstr Surg 1988;81:233-9.
13. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963;61:882-8.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
15. Braunwald E. Stunning of the myocardium: an update. Cardiovasc Drugs Ther 1991;5:849-51.
16. Kuzelová M, Svec P. Ischemia-reperfusion tissue injuries and possibilities of pharmacologic intervention. Cesk Fysiol 2001;50:11-8. [Abstract]
17. Baxter GF. The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on. Basic Res Cardiol 2002;97:268-75.
18. Okazaki Y, Cao ZL, Ohtsubo S, Hamada M, Naito K, Rikitake K, et al. Leukocyte-depleted reperfusion after long cardioplegic arrest attenuates ischemia-reperfusion injury of the coronary endothelium and myocardium in rabbit hearts. Eur J Cardiothorac Surg 2000;18:90-7.
19. Fischer UM, Cox CS Jr, Allen SJ, Stewart RH, Mehlhorn U, Laine GA. The antioxidant N-acetylcysteine preserves myocardial function and diminishes oxidative stress after cardioplegic arrest. J Thorac Cardiovasc Surg 2003;126:1483-8.
20. Heidrich H, Gerke E, Nekarda H. Platelet aggregation inhibition with calcium dobesilate. Arzneimittelforschung 1983;33:580-2. [Abstract]
21. Vinazzer H, Hachen HJ. Influence of calcium dobesilate (Doxium) on blood viscosity and coagulation parameters in diabetic retinopathy. Vasa 1987;16:190-2.
22. Benarroch IS, Brodsky M, Rubinstein A, Viggiano C, Salama EA. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res 1985;17:131-8.
23. Vojnikovic B. Hyperviscosity in whole blood, plasma, and aqueous humor decreased by doxium (calcium dobesilate) in diabetics with retinopathy and glaucoma: a double-blind controlled study. Ophthalmic Res 1984;16:150-62.
24. Barras JP, Graf C. Hyperviscosity in diabetic retinopathy treated with Doxium (calcium dobesilate). Vasa 1980; 9:161-4.
25. Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macroand microvascular endothelial cells. Br J Pharmacol 1997;122:1502-8.
26. Brunet J, Farine JC, Garay RP, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998;12:205-12.
27. Bozkurt AK, Konukoğlu D, Ustündağ N, Yüceyar L, Mayda AS. Calcium dobesilate ameliorates lung injury following lower limb ischemia/reperfusion. Drugs Exp Clin Res 2002;28:127-32.
28. Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, et al. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol 2001;428:277-86.
29. Del Maestro RF.Role of superoxide anion radicals in microvascular permeability and leukocyte behavior. Can J Physiol Pharmacol 1982;60:1406-14.
30. Ruiz E, Tejerina T. Calcium dobesilate increases endotheliumdependent relaxation in endothelium-injured rabbit aorta. Pharmacol Res 1998;38:361-6.
31. Brunet J, Farine JC, Garay RP, Hannaert P. Angioprotective action of calcium dobesilate against reactive oxygen speciesinduced capillary permeability in the rat. Eur J Pharmacol 1998;358:213-20.
32. Huttl K, Hollenberg NK. Effect of CLS 2210 (calcium dobesilate) on survival and myocardial infarction size in the rat: influence of dose and duration of treatment. Cardiology 1992;80:28-33.
33. Nikitopoulou-Maratou G, Lymperi M, Poyatzi A, Molyvdas PA. Calcium dobesilate and transmembrane potential in canine cardiac cells. A preliminary study. Arzneimittelforschung 1986;36:1345-7.
34. Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 1954;37:171-85.
35. Edmunds LH. Myocardial protection management during adult cardiac operations. In: Baue AE, Geha AS, Hammond GL, Laks H, Naunheim KS, Glenn WWL editors. Glenn’s thoracic and cardiovascular surgery. 6th ed. Missouri: Prentice Hall Int; 1996. p. 1631-53.
36. Ford-Hutchinson AW. Leukotrienes: their formation and role as inflammatory mediators. Fed Proc 1985;44:25-9.
37. Ford-Hutchinson AW, Rackman A. Leukotrienes as mediators of skin inflammation. Br J Dermatol 1983;109 Suppl 25:26-9.
38. Damon M, Flandre O, Michel F, Perdrix L, Labrid C, Crastes de Paulet A. Effect of chronic treatment with a purified flavonoid fraction on inflammatory granuloma in the rat. Study of prostaglandin E2 and F2 alpha and thromboxane B2 release and histological changes. Arzneimittelforschung 1987;37:1149-53.
39. Korthuis RJ, Gute DC. Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: cellular mechanisms and effect of Daflon 500 mg. Int J Microcirc Clin Exp 1997;17 Suppl 1:11-7.